George Mason University is uniquely positioned for discovering novel antibiotic leads and druggable targets to counter the growing challenge of antibiotic resistance and forestall a post-antibiotic era. We have assembled a multidisciplinary team with extensive experience in the fields of proteomics, mass spectrometry, materials science, microbiology, molecular biology, and biochemistry. We have developed a powerful suite of technologies and expertise for large-scale analyses of biomolecules for the discovery, assessment, and validation of novel antimicrobials. Our discovery process, which combines nanoparticle-based peptide enrichment with advanced mass spectrometry allows us to identify potential antimicrobial peptides that would be virtually undetectable using conventional discovery methods. Furthermore, our team is capable of evaluating the performance starting with initial testing at the lab bench all the way through testing in animal infection models.